DMAC
Price
$9.65
Change
+$0.29 (+3.10%)
Updated
Nov 9 closing price
Capitalization
504.74M
2 days until earnings call
Intraday BUY SELL Signals
TSHA
Price
$4.37
Change
+$0.04 (+0.92%)
Updated
Nov 9 closing price
Capitalization
1.41B
2 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DMAC vs TSHA

DMAC vs TSHA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DMAC vs. TSHA commentary
Nov 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a StrongBuy and TSHA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for DMAC with price predictions
Nov 09, 2026

DMAC's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for DMAC turned positive on October 22, 2026. Looking at past instances where DMAC's MACD turned positive, the stock continued to rise in 49 of 50 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DMAC as a result. In 84 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The 50-day moving average for DMAC moved above the 200-day moving average on October 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +6.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 218 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 131 of 159 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Bearish Trend Analysis

The 10-day RSI Indicator for DMAC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 24 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 58 cases where DMAC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

DMAC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.166) is normal, around the industry mean (3.498). P/E Ratio (-13.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for TSHA with price predictions
Nov 09, 2026

TSHA sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for TSHA moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 53 cases where TSHA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TSHA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TSHA's RSI Indicator exited the oversold zone, 30 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on TSHA as a result. In 69 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for TSHA just turned positive on October 21, 2026. Looking at past instances where TSHA's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.

Following a +6.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSHA advanced for three days, in 213 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

TSHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.643) is normal, around the industry mean (3.498). P/E Ratio (-10.561) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (440.869).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. TSHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TSHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
DMAC vs TSHA: Fundamental Ratings
DMAC
TSHA
OUTLOOK RATING
1..100
3821
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
22
Undervalued
PROFIT vs RISK RATING
1..100
32100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
3563
P/E GROWTH RATING
1..100
8221
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TSHA's Valuation (22) in the null industry is somewhat better than the same rating for DMAC (69) in the Biotechnology industry. This means that TSHA’s stock grew somewhat faster than DMAC’s over the last 12 months.

DMAC's Profit vs Risk Rating (32) in the Biotechnology industry is significantly better than the same rating for TSHA (100) in the null industry. This means that DMAC’s stock grew significantly faster than TSHA’s over the last 12 months.

TSHA's SMR Rating (98) in the null industry is in the same range as DMAC (99) in the Biotechnology industry. This means that TSHA’s stock grew similarly to DMAC’s over the last 12 months.

DMAC's Price Growth Rating (35) in the Biotechnology industry is in the same range as TSHA (63) in the null industry. This means that DMAC’s stock grew similarly to TSHA’s over the last 12 months.

TSHA's P/E Growth Rating (21) in the null industry is somewhat better than the same rating for DMAC (82) in the Biotechnology industry. This means that TSHA’s stock grew somewhat faster than DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMACTSHA
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
82%
Declines
ODDS (%)
Bearish Trend 11 days ago
81%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Nov 10, 2026
Stock price -- (DMAC: $9.36 vs. TSHA: $4.37)
Brand notoriety: DMAC and TSHA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMAC: 63% vs. TSHA: 93%
Market capitalization -- DMAC: $504.74M vs. TSHA: $1.41B
DMAC [@Biotechnology] is valued at $504.74M. TSHA’s [@Biotechnology] market capitalization is $1.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMAC’s FA Score shows that 1 FA rating(s) are green while TSHA’s FA Score has 2 green FA rating(s).

  • DMAC’s FA Score: 1 green, 4 red.
  • TSHA’s FA Score: 2 green, 3 red.
According to our system of comparison, TSHA is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMAC’s TA Score shows that 5 TA indicator(s) are bullish while TSHA’s TA Score has 5 bullish TA indicator(s).

  • DMAC’s TA Score: 5 bullish, 4 bearish.
  • TSHA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both DMAC and TSHA are a good buy in the short-term.

Price Growth

DMAC (@Biotechnology) experienced а +1.19% price change this week, while TSHA (@Biotechnology) price change was +9.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.

Reported Earning Dates

DMAC is expected to report earnings on Nov 12, 2026.

TSHA is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+2.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with ANNX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then ANNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+3.10%
ANNX - DMAC
47%
Loosely correlated
+0.71%
EDIT - DMAC
47%
Loosely correlated
+7.00%
TSHA - DMAC
45%
Loosely correlated
+0.92%
VIR - DMAC
44%
Loosely correlated
+11.75%
SLDB - DMAC
44%
Loosely correlated
+6.53%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INR13.170.38
+2.97%
Infinity Natural Resources Inc
PI174.733.70
+2.16%
Impinj
UVSP41.090.62
+1.53%
Univest Financial Corp
RELX40.02-0.15
-0.37%
Relx PLC
HUIZ2.26-0.03
-1.10%
Huize Holding Limited